No Early Cancer Risk Seen from Contaminated Valsartan
(MedPage Today) -- Cohort study reassures, but FDA notes a second contaminant (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - September 14, 2018 Category: American Health Source Type: news
FDA Finds Another Carcinogen in Certain Valsartan Heart Meds
FRIDAY, Sept. 14, 2018 -- There ' s more bad news for Americans who took certain brands of the common blood pressure medication valsartan.
The U.S. Food and Drug Administration on Thursday warned that it has found a second impurity in three lots of... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 14, 2018 Category: General Medicine Source Type: news
No Short-Term Cancer Risk From Recalled Heart Med Valsartan: Study
Title: No Short-Term Cancer Risk From Recalled Heart Med Valsartan: StudyCategory: Health NewsCreated: 9/13/2018 12:00:00 AMLast Editorial Review: 9/14/2018 12:00:00 AM (Source: MedicineNet High Blood Pressure General)
Source: MedicineNet High Blood Pressure General - September 14, 2018 Category: Cardiology Source Type: news
FDA finds another impurity in recalled heart drug
The US Food and Drug Administration said it found additional "unexpected impurity" in three lots of Torrent Pharmaceuticals' recalled valsartan drug. (Source: CNN.com - Health)
Source: CNN.com - Health - September 14, 2018 Category: Consumer Health News Source Type: news
FDA provides update on its ongoing investigation into valsartan products; and reports on the finding of an additional impurity identified in one firm ’s already recalled products
FDA update on the ongoing investigation into valsartan impurities, recalls and current findings. (Source: Food and Drug Administration)
Source: Food and Drug Administration - September 13, 2018 Category: American Health Source Type: news
Tainted Valsartan Not Linked to Cancer Risk in the Short Term Tainted Valsartan Not Linked to Cancer Risk in the Short Term
An expedited short-term analysis finds no increased risk for cancer in patients who took NDMA-contaminated valsartan, but uncertainty remains for colorectal and uterine cancer. The EMA weighs in.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 13, 2018 Category: Consumer Health News Tags: Cardiology News Source Type: news
No Apparent Short-Term Cancer Risk From Recalled Valsartan
THURSDAY, Sept. 13, 2018 -- Users of valsartan contaminated with N-nitrosodimethylamine (NDMA) seem not to have increased cancer risk, according to a study published online Sept. 12 in The BMJ.
Anton Potteg ård, Ph.D., from the University of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 13, 2018 Category: Pharmaceuticals Source Type: news
FDA, EMA Valsartan Update, New Data on Cancer Risk FDA, EMA Valsartan Update, New Data on Cancer Risk
The FDA and EMA report a possible second carcinogen in previously withdrawn vasartan products, while a new analysis finds no increased cancer risk in those who previously took contaminated valsartan.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - September 13, 2018 Category: Cardiology Tags: Cardiology News Source Type: news
No Short-Term Cancer Risk From Recalled Valsartan
The U.S. Food and Drug Administration in July recalled valsartan medicines manufactured by the Chinese company Zhejiang Huahai Pharmaceuticals. (Source: WebMD Health)
Source: WebMD Health - September 13, 2018 Category: Consumer Health News Source Type: news
No Short - Term Cancer Risk From Recalled Heart Med Valsartan: Study
(Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - September 13, 2018 Category: Cancer & Oncology Tags: Cardiology, Family Medicine, Oncology, Pharmacy, News, Source Type: news
2nd possible carcinogen found in recalled blood pressure drug valsartan, Health Canada says
A second impurity that is a classified as a probable human carcinogen has been found in valsartan, manufactured by Zhejiang Huahai Pharmaceuticals in China, Health Canada announces. (Source: CBC | Health)
Source: CBC | Health - September 13, 2018 Category: Consumer Health News Tags: News/Health Source Type: news
No Short-Term Cancer Risk From Recalled Heart Med Valsartan: Study
THURSDAY, Sept. 13, 2018 -- People who took recalled blood pressure drugs containing a carcinogen do not appear to have a markedly increased short-term risk of cancer, a new study reports.
Doctors are reluctant to say they ' re fully in the clear,... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 13, 2018 Category: General Medicine Source Type: news
Withdrawn valsartan meds not linked to short-term cancer risk
Expedited analysis of NDMA-contaminated products finds no markedly raised short-term cancer risk Related items fromOnMedica GPs defend practice on prescribing statins Too few women take part in many CVD clinical trials MHRA tightens licence restrictions on valproate for women Cancer patients using complementary meds die sooner Drugs regulators “put profits before patients” (Source: OnMedica Latest News)
Source: OnMedica Latest News - September 13, 2018 Category: UK Health Source Type: news
No Short-Term Cancer Risk From Recalled Heart Med Valsartan: Study
(Source: Cancercompass News: Other Cancer)
Source: Cancercompass News: Other Cancer - September 13, 2018 Category: Cancer & Oncology Source Type: news
Blood pressure pills recalled worldwide 'does NOT boost the risk of cancer'
Researchers from the University of Southern Denmark found that people who take the medicine valsartan for around four years are not more likely to develop cancer. (Source: the Mail online | Health)
Source: the Mail online | Health - September 12, 2018 Category: Consumer Health News Source Type: news
